Drug Trial Radar · NCT07480733
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Nov 30, 2027
Study completion Nov 11, 2028
Sponsor
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and preliminary efficacy of JS212, JS213, as well as JS212 in combination with JS213, toripalimab, and JS207.
Conditions
- Advanced Malignant Solid Tumors
Interventions
JS212 for InjectionDrug
administered by intravenous infusion on Day 1 of each 21-day cycle.
JS213 for InjectionDrug
administered by intravenous infusion on Day 1 of each 21-day cycle.
JS207 for InjectionDrug
administered by intravenous infusion on Day 1 of each 21-day cycle.
ToripalimabDrug
administered by intravenous infusion on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to 6 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.